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ost-Transplant Lymphoproliferative Disorder
imicking a Thrombotic Microangiopathy
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gThe thrombotic microangiopathies (TMAs) com-
rise a group of disorders characterized by the forma-
ion of platelet-ﬁbrin thrombi within the microcircu-
ation [1]. Clinical features depend on the distribution
f involved vascular beds, but the hallmark sign is a
icroangiopathic hemolytic anemia characterized by
he presence of schistocytes. After bone marrow trans-
lantation, many diagnoses can overlap when anemia,
hrombocytopenia, fever, renal failure, and neurologic
ysfunction occur. An operational deﬁnition for TMA
ased on these criteria has recently been proposed [2].
urther, patients diagnosed with TMA have a greater
requency of transplant-related complications, severe
cute graft-versus-host disease (GVHD), and systemic
nfections [3,4].
However, this is the same clinical setting where
ost-transplant lymphoproliferative disorder (PTLD)
evelops [5,6]. PTLD may present in a myriad of ways
nd infection complicates many cases. We present a
ase of a PTLD with central nervous system (CNS)
nd gastrointestinal (GI) tract involvement with an
ngiocentric pattern mimicking a TMA.
A 33-year-old man diagnosed with Ph chronic
yeloid leukemia received an autologous stem cell
ransplant conditioned with busulfan as part of a ran-
omized trial (16 mg/kg per day for 4 days). After
ransplantation, he received cytarabine and interferon
aintenance therapy for 6 months, with no response.
ive months later, imatinib (400 mg/d) was started,
chieving a complete hematologic response but no
ytogenetic response. In contrast, chromosomal evo-
ution with a second Ph and a 8 chromosome was
bserved, despite increasing the imatinib (800 mg/d)
ose for 6 months.
In this case, the patient received a granulocyte
olony-stimulating factor-mobilized peripheral blood
tem cell transplant (SCT) from a partly HLA-
atched (1/6 HLA antigen mismatched) unrelated
ale donor, because no HLA-identical donor was
vailable. The graft was immunomanipulated for the
ositive selection of CD34 cells. The graft contained
.1  106 CD34 and 0.16  106 CD3 cells per
ilogram. The conditioning regimen included thio-
epa 400 mg/kg twice on day 1, oral busulfan 4 mg/kg cer day for 4 days, cyclophosphamide 60 mg/kg per
ay for 2 days, and anti-thymocyte globulin (ATG) 1.5
g/kg per day for 3 days. Cyclosporine (CsA) was
iven for GVHD prophylaxis. Neutrophil (0.5 
09/L) and platelet (20  109/L) engraftments were
chieved on days 12 and 14, respectively. On day
15 the patient developed grade III acute GvHD with
kin, GI, and liver involvement, initially controlled
ith methylprednisolone 2 mg/kg per day. Bone mar-
ow study on day 28 showed complete donor chi-
erism, although polymerase chain reaction (PCR)
emained positive for the BCR-ABL rearrangement.
On day 40 (December 30, 2002), cytomegalovi-
us antigenemia showed 70 positive cells and intrave-
ous ganciclovir was started (the patient was receiving
ral acyclovir as prophylactic therapy). Three days
ater, the patient developed neurologic symptoms (al-
ered mental status, no focal deﬁcits, no nuchal rigid-
ty) and magnetic resonance (MR) images demon-
trated high-signal intensities in the left temporal
obe. Cerebrospinal ﬂuid (CSF) examination (January
, 2003) showed 2000 red blood cells/mm3, without
eukocytes and with normal levels of protein and glu-
ose. On this basis, herpetic encephalitis was sus-
ected, but a deﬁnite diagnosis could not be made and
he antiviral treatment was not changed. PCR tests in
he CSF for herpes simplex virus, herpes viruses 6, 7,
nd 8, cytomegalovirus, and Epstein-Barr virus (EBV)
ere performed and all were negative. Due to wors-
ning of GVHD manifestations, treatment with rabbit
TG (2 mg/kg per day for 6 days) was started on day
54. A progressively favorable response was achieved
y maintaining CsA treatment and slowly tapering the
orticosteroid schedule.
On day 84 after SCT, intravascular hemolytic
nemia was diagnosed (7.8 g/dL hemoglobin, 1053
U/L serum lactate dehydrogenase, 1.3 mg/dL total
erum bilirubin, and negative direct Coombs test re-
ult). Platelet count decreased to 20  109/L and the
lood smear showed 6% schistocytes. TMA was sus-
ected. Doses of CsA and steroids were decreased.
ransfusion requirements increased, lactate dehydro-
enase reached 1250 UI/L, and total bilirubin in-
reased to 2.7 mg/dL, with 5%-6% schistocyte count
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Letter to the Editor1204n the blood smear. On day 94, the patient devel-
ped generalized seizures. With these observations,
ransplantation-associated (TA) TMA was established
nd CsA was withdrawn. Fresh frozen plasma ex-
hange was initiated. Cranial magnetic resonance MR
maging showed a nodular hyperintensity at the gray
atter-white matter junction, in the cerebellum, pons,
nd vermis, and in the left occipital lobe (see axial ﬂair
mages in Figure 1). CSF examination was negative for
acterial meningitis and serologic PCR tests for Herpes
implex, Herpes zoster, and Toxoplasma gondii were
lso negative. Immunoﬂuorescence determinations were
egative for EBV and West Nile virus immunoglob-
lin M antibodies. On day 97 the patient developed
I bleeding from 3 gastric ulcers that were treated
ith sclerotherapy (day 104). A PCR test for EBV
as positive in the CSF taken on March 3, 2003
103). However, PCR was negative in the blood
ample obtained the same day. On day 108 the
atient died from GI bleeding.
Necropsy revealed several necrohemorrhagic ul-
ers in the GI tract and focal hemorrhagic lesions in
he CNS (Figure 2) corresponding to images provided
y MR imaging. Histologic study of these CNS and
I lesions showed lymphoid proliferation composed
f large lymphoid cells with an angiocentric pattern.
mmunophenotyping studies showed a B cell pheno-
ype (CD20, CD3, bcl2, CD10, bcl6. and p53).
n addition, the presence of EBV was demonstrated by
mmunohistochemical latent membrane protein-1Figure 1. A, B, Cerebral MR axial ﬂair images show nodular hyperintLMP-1) (EBV-associated antigen) detection and by
n in situ hybridization Epstein-Barr early RNA
EBER) test. Although, no conclusive evidence could
e found about donor or recipient origin, a monomor-
hic B cell, post-SCT, EBV-associated lymphoprolif-
rative disease was diagnosed.
TMA includes many different clinical scenarios,
articularly after SCT [7]. It not only refers to the
haracteristic thrombotic thrombocytopenic purpura
TTP) or hemolytic uremic syndrome but also includes
eatures induced by CsA therapy, severe GVHD, or
arious angioinvasive infections such as cytomegalo-
irus infection or aspergillosis [4,8]. The pathogenesis
f TMA is probably heterogeneous in different disor-
ers. Although in TTP the von Willebrand factor-
leaving protease ADAMTS13 appears to be deﬁcient,
uch deﬁciency has not been observed after SCT [9]
nd the use of plasma exchange is associated with poor
esults. Therefore, once TA-TMA is suspected, a correct
tiologic differential diagnosis should be attempted.
In the severely immunosuppressed patient de-
cribed in this report, the increased transfusion re-
uirements associated with the laboratory ﬁndings led
s to a TA-TMA diagnosis. Moreover, image studies
id not provide a clear differential diagnosis; on the
ontrary, an ongoing TTP process with neurologic
nd GI manifestations was suspected. Further, CsA
ithdrawal and plasma exchange therapy did not re-
ult in any therapeutic beneﬁt. Unfortunately, an ad-ensities in the cerebellum, pons, vermis, and left occipital lobe.
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Letter to the Editor 1205quate diagnosis of PTLD was made only in the nec-
opsy study.
The spectrum of PTLD ranges widely, from an
ndolent form to a devastating disseminated disease.
TLD may mislead the clinician due to the mimick-
ng of features of several other disorders. Thus, once
uspected, a tissue biopsy is strongly recommended.
ur patient met some of the recognized risk factors
or PTLD development (unrelated donor, HLA-mis-
atching, ATG therapy, development of GVHD).
owever, laboratory ﬁndings and the presence of
chistocytes in our patient suggested TA-TMA rather
han PTLD. A patient with an angiotropic large cell
ymphoma who developed a TMA has been reported
y Sill et al [10]. To our knowledge, no other case of
TLD as a cause of TA-TMA has been reported to
ate.
We would like to emphasize that the onset of a
igure 2. Necropsy images show focal hemorrhagic lesions in the
entral nervous system that correspond to the MR images.TLD after SCT can mimic a TA-TMA, and it Mhould be included in the differential diagnosis when
chistocytes and other laboratory ﬁndings of TMA are
bserved. Diagnostic imaging procedures and tissue
iopsies should be conducted to establish an appro-
riate diagnosis and to undertake speciﬁc treatment in
hese severely ill patients.
EFERENCES
1. Daly AS, Xenocostas A, Lipton JH. Transplantation-associated
thrombotic microangiopathy: twenty-two years later. Bone
Marrow Transplant. 2002;30:709-715.
2. Ho VT, Cutler C, Carter S, et al. Blood and marrow transplant
clinical trials network toxicity committee consensus summary:
thrombotic microangiopathy after hematopoietic stem cell
transplantation. Biol Blood Marrow Transplant. 2005;11:571-575.
3. Pettitt AR, Clark RE. Thrombotic microangiopathy following
bone marrow transplantation. Bone Marrow Transplant. 1994;
14:495-504.
4. Roy V, Rizvi MA, Vesely SK, George JN. Thrombotic throm-
bocytopenic purpura-like syndromes following bone marrow
transplantation: an analysis of associated conditions and clinical
outcomes. Bone Marrow Transplant. 2001;27:641-646.
5. Curtis RE, Travis LB, Rowlings PA, et al. Risk of lymphopro-
liferative disorders after bone marrow transplantation: a multi-
institutional study. Blood. 1999;94:2208-2216.
6. Chiang KY, Hazlett LJ, Godder KT, et al. Epstein-Barr virus-
associated B cell lymphoproliferative disorder following mis-
matched related T cell-depleted bone marrow transplantation.
Bone Marrow Transplant. 2001;28:1117-1123.
7. George JN, Li X, McMinn JR, Terrell DR, Vesely SK, Selby
GB. Thrombotic thrombocytopenic purpura-hemolytic uremic
syndrome following allogeneic HPC transplantation: a diagnos-
tic dilemma. Transfusion. 2004;44:294-304.
8. Nishida T, Hamaguchi M, Hirabayashi N, et al. Intestinal
thrombotic microangiopathy after allogeneic bone marrow
transplantation: a clinical imitator of acute enteric graft-versus-
host disease. Bone Marrow Transplant. 2004;33:1143-1150.
9. George JN, Selby GB. Thrombotic microangiopathy after al-
logeneic bone marrow transplantation: a pathologic abnormal-
ity associated with diverse clinical syndromes. Bone Marrow
Transplant. 2004;33:1073-1074.
0. Sill H, Hoﬂer G, Kaufmann P, et al. Angiotropic large cell
lymphoma presenting as thrombotic microangiopathy (throm-
botic thrombocytopenic purpura). Cancer. 1995;75:1167-1170.
afael Carrion, MD
one Marrow Transplantation Unit
epartment of Oncology
ospital General Universitario Gregorio Marañón
adrid, Spain
